Sources
email://101694
CCXI — Research (2026)
2026-09-07T00:00:00Z
2026-09-15T18:00:00Z
ccxi
tli
research
biotech
What changed in the latest update +1 −0
@@ -5 +5 @@ created: '2026-09-07T00:00:00Z'
@@ -33,0 +34 @@ CCXI (ChemoCentryx) covered by TLI. TLI not making a recommendation - just keepi
+
new section
edited section
· markers reflect the latest update
Summary
CCXI (ChemoCentryx) covered by TLI. TLI not making a recommendation - just keeping members informed as popularity grows. Chart looks good: Wave 2 pulled back to 50 Day MA and 0.618 Fib at $13.72.
TLI Analysis
- TLI not making a recommendation - just tracking popularity
- Chart does look good - Wave 2 pulled back to 50 Day MA and 0.618 Fib at $13.72
- Breakaway target to $19
- Wave 3 target: 1.618 Fib at $28
- TLI wants members to focus on current positions and prepare for September weakness
Position Context
- Conviction: star - disclaimer given
- Key levels: $13.72 (Wave 2 support), $19 (breakaway), $28 (Wave 3 target)
Price Check edited
- 2026-09-08 (close) — $14.05 (+4.87% bounce from Sep 4 close). Above 0.618 Fib at $13.72 — bullish. Wave 3 target $28 remains valid. TLI disclaimer still applies.
- Type: Biotech